P
ProHub
English 简体中文 繁體中文
Medium Market Entry Pricing Competitive Response

New Vaccine

#Healthcare
ProHub Comment

This is a quantitative market entry case requiring candidates to move beyond basic calculations toward strategic cost-benefit analysis. The key insight is recognizing that the vaccine is only cost-effective for certain baby weight segments, making selective market capture critical to viability.

Estimated Time 26 minutes
Difficulty Medium
Source Chicago Booth
22 / 100
Our client is a large pharmaceutical corporation, and they have developed a new vaccine that prevents low birth weight infants from contracting staph infections. They have approached us to determine the potential for this vaccine.

Clarifying Information

  1. When the candidate asks what is meant by the ‘potential for this vaccine,’ explain that our client is looking for clarity around revenue potential and a cost-benefit analysis of administering the vaccine.
  2. Our client is looking to launch this product in the United States, and is not currently concerned about international potential.
Mock Interview
Interviewer

Our client is a large pharmaceutical corporation, and they have developed a new vaccine that prevents low birth weight infants from contracting staph infections. They have approached us to determine the potential for this vaccine.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

A pharmaceutical company seeks to determine revenue potential for a new staph infection vaccine targeting low birth weight infants. The analysis reveals that vaccine cost-effectiveness varies dramatically by infant weight segment, with vaccination viable only for the smallest babies and one middle segment, constraining realistic revenue to $300M-$600M rather than the initially calculated $3B.

Key Insights:

  1. Segmentation analysis is critical—the same product has vastly different value propositions across different customer segments
  2. Cost-benefit analysis must compare the vaccine against realistic alternatives (antibiotics) rather than theoretical total addressable market
  3. Market capture for segments where the alternative is cheaper will be limited, requiring either government mandates or a marketing strategy emphasizing non-financial benefits
  4. Strong candidates recognize that pricing at cost of administration ($6K) may not translate to equivalent revenue capture when cheaper alternatives exist